Last updated on July 2019
Study of Ibrutinib and Rituximab in Treatment Na ve Follicular Lymphoma
Brief description of study
The purpose of this study is to evaluate whether the addition of ibrutinib will result in prolongation of progression-free survival (PFS) when compared with rituximab alone in treatment nave subjects with follicular lymphoma.
Clinical Study Identifier: NCT02947347
Start Over
Connect »
